stockportfolio.pro
Stocks / FDMT vs NGNE
FDMT vs NGNE
4D Molecular Therapeutics, Inc. and Neurogene Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| 4D Molecular Therapeutics, Inc. (FDMT) | Neurogene Inc. (NGNE) | |
|---|---|---|
| Market cap | $0.4B | $0.5B |
| Revenue (latest FY) | $85.21M | $0 |
| Net income (latest FY) | $-140.11M | $-90.35M |
| Revenue growth (5y CAGR) | 44.3% | — |
| Net margin | -164.4% | — |
| Return on equity | -27.7% | -34.1% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open FDMT — free Open NGNE — freeFrequently asked questions
Which is bigger, FDMT or NGNE?
Neurogene Inc. is larger by market capitalization — $0.5B versus $0.4B.
Which grows faster, FDMT or NGNE?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.